On Monday, Shares of Groupon, Inc. (NASDAQ:GRPN), lost -0.80% to $4.93.
Groupon declared the launch of Beauty Week: a week-long celebration focused on looking and feeling great, at an unbeatable value. Offers span all health and beauty categories, ranging from spa packages, hair removal and weight loss treatments to rejuvenation and salon services.
“Beauty Week at Groupon curates some of the absolute best salons, spas and rejuvenation experiences — at an unbeatable value — all across the country,” said Silvija Martincevic, vice president and General Manager of Health, Beauty and Wellness at Groupon. “And the expansion of our booking capabilities provides a smooth experience from purchase to appointment.”
Shoppers can find even bigger savings during Beauty Week with the following promo codes:
- July 27 and 28: An extra 20 percent off beauty and spa deals with the promo code GLAM20
- July 29 and 30: $10 off facial and massage deals with the promo code TREAT10
- July 31: Select deals will be sold for only $10 throughout the entire day
- August 1 and 2: Up to an extra 30 percent off select beauty and spa deals.
Groupon, Inc. operates online local commerce marketplaces that connect merchants to consumers by offering goods and services at a discount worldwide. It also offers deals on products for which it acts as the merchant of record.
Shares of The Charles Schwab Corporation (NYSE:SCHW), declined -2.10% to $34.08, during its last trading session.
The Charles Schwab Corporation declared recently that its net income for the second quarter of 2015 was $353 million, up 17% from $302 million for the first quarter of 2015, and up 9% from $324 million for the second quarter of 2014. Net income for the six months ended June 30, 2015 was $655 million, up 1% from the year-earlier period. The company’s financial results for the second quarter and first six months of 2015 comprise litigation proceeds of about $17 million (comprised of in Other revenue) regarding the company’s non-agency residential mortgage-backed securities portfolio; this raised earnings per share by $0.01.
CEO Walt Bettinger said, Our contemporary full-service investing model continues to appeal to clients and prospects, and assisted us achieve strong quarterly operating results in the face of sideways equity markets and ongoing low interest rates. We gathered $37.0 billion of core net new assets, the highest second quarter in our history, and maintained a 6% annualized organic growth rate despite seasonal tax outflows in April. Clients opened 280,000 new brokerage accounts, up 16% year-over-year and another second quarter record. Total client assets were $2.54 trillion at quarter-end, up 6% from a year ago. Client assets under the guidance of a registered independent advisor or enrolled in one of our retail or other advisory solutions also rose 6% year-over-year, to $1.26 trillion. At month-end June, we were serving 9.6 million brokerage accounts, 1.0 million banking accounts, and 1.5 million retirement plan participants, up 4%, 6% and 10%, respectively, from the second quarter of 2014.
The Charles Schwab Corporation, through its auxiliaries, provides wealth administration, securities brokerage, banking, money administration, and financial advisory services. The company operates through two segments, Investor Services and Advisor Services.
Finally, INSYS Therapeutics, Inc. (NASDAQ:INSY), ended its last trade with -1.27% loss, and closed at $42.79.
Insys Therapeutics declared that the Company will release its financial results for the second quarter 2015 on Thursday, August 6, 2015, before the U.S. financial markets open.
Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients; and Dronabinol SG Capsule, a dronabinol soft gelatin capsule that is generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
